Dalfampridine
- Generic Name
- Dalfampridine
- Brand Names
- Ampyra, Fampyra, Fampridine Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C5H6N2
- CAS Number
- 504-24-5
- Unique Ingredient Identifier
- BH3B64OKL9
Overview
Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Background
Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Indication
Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS).
Associated Conditions
- Multiple Sclerosis
Clinical Trials
FDA Approved Products
DALFAMPRIDINE
Manufacturer:Micro Labs Limited
Route:ORAL
Strength:10 mg in 1 1
Approved: 2022/11/28
NDC:42571-275
Dalfampridine
Manufacturer:Actavis Pharma, Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2021/12/02
NDC:0591-2533
Dalfampridine
Manufacturer:Golden State Medical Supply, Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2024/02/12
NDC:51407-876
Dalfampridine
Manufacturer:Sun Pharmaceutical Industries, Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2023/10/16
NDC:62756-429
Dalfampridine
Manufacturer:Accord Healthcare Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2024/01/04
NDC:16729-292
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath